Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery

Jinghua Duan,1,2 Frederick G Vogt,3 Xiaojian Li,1 Don Hayes Jr,4,5 Heidi M Mansour6 1University of Kentucky College of Pharmacy, Department of Pharmaceutical Sciences – Drug Development Division, Lexington, KY, USA; 2University of Washington-Seattle, College of Pharmacy, Department of Phar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Duan J, Vogt FG, Li X, Hayes D Jr, Mansour HM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/69cb2ec632664caaa185b111daa0b725
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:69cb2ec632664caaa185b111daa0b725
record_format	dspace
spelling	oai:doaj.org-article:69cb2ec632664caaa185b111daa0b7252021-12-02T00:53:29ZDesign, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery1176-91141178-2013https://doaj.org/article/69cb2ec632664caaa185b111daa0b7252013-09-01T00:00:00Zhttp://www.dovepress.com/design-characterization-and-aerosolization-of-organic-solution-advance-a14380https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Jinghua Duan,1,2 Frederick G Vogt,3 Xiaojian Li,1 Don Hayes Jr,4,5 Heidi M Mansour6 1University of Kentucky College of Pharmacy, Department of Pharmaceutical Sciences – Drug Development Division, Lexington, KY, USA; 2University of Washington-Seattle, College of Pharmacy, Department of Pharmaceutics, Seattle, WA, USA; 3GlaxoSmithKline, Analytical Sciences, Product Development, King of Prussia, PA, USA; 4The Ohio State University College of Medicine, Departments of Pediatrics and Internal Medicine, Nationwide Children's Hospital Lung and Heart-Lung Transplant Programs, Columbus, OH, USA; 5The Ohio State University, Davis Heart and Lung Research Institute, Columbus, OH, USA; 6The University of Arizona–Tucson, College of Pharmacy, Skaggs Center of Pharmaceutical Sciences, Tucson, AZ, USA Abstract: The aim of this study was to design and develop respirable antibiotics moxifloxacin (MOXI) hydrochloride and ofloxacin (OFLX) microparticles and nanoparticles, and multifunctional antibiotics particles with or without lung surfactant 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) for targeted dry powder inhalation delivery as a pulmonary nanomedicine. Particles were rationally designed and produced by advanced spray-drying particle engineering from an organic solution in closed mode (no water) from dilute solution. Scanning electron microscopy indicated that these particles had both optimal particle morphology and surface morphology, and the particle size distributions were suitable for pulmonary delivery. Comprehensive and systematic physicochemical characterization and in vitro aerosol dispersion performance revealed significant differences between these two fluoroquinolone antibiotics following spray drying as drug aerosols and as cospray-dried antibiotic drug: DPPC aerosols. Fourier transform infrared spectroscopy and confocal Raman microspectroscopy were employed to probe composition and interactions in the solid state. Spray-dried MOXI was rendered noncrystalline (amorphous) following organic solution advanced spray drying. This was in contrast to spray-dried OFLX, which retained partial crystallinity, as did OFLX:DPPC powders at certain compositions. Aerosol dispersion performance was conducted using inertial impaction with a dry powder inhaler device approved for human use. The present study demonstrates that the use of DPPC offers improved aerosol delivery of MOXI as cospray-dried microparticulate/nanoparticulate powders, whereas residual partial crystallinity influenced aerosol dispersion of OFLX and most of the compositions of OFLX:DPPC inhalation powders. Keywords: lung infection, respiratory, lung surfactant, solid-state particle engineering design, aerosol, fluoroquinolone antibiotic drug deliveryDuan JVogt FGLi XHayes D JrMansour HMDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2013, Iss default, Pp 3489-3505 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Duan J Vogt FG Li X Hayes D Jr Mansour HM Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery
description	Jinghua Duan,1,2 Frederick G Vogt,3 Xiaojian Li,1 Don Hayes Jr,4,5 Heidi M Mansour6 1University of Kentucky College of Pharmacy, Department of Pharmaceutical Sciences – Drug Development Division, Lexington, KY, USA; 2University of Washington-Seattle, College of Pharmacy, Department of Pharmaceutics, Seattle, WA, USA; 3GlaxoSmithKline, Analytical Sciences, Product Development, King of Prussia, PA, USA; 4The Ohio State University College of Medicine, Departments of Pediatrics and Internal Medicine, Nationwide Children's Hospital Lung and Heart-Lung Transplant Programs, Columbus, OH, USA; 5The Ohio State University, Davis Heart and Lung Research Institute, Columbus, OH, USA; 6The University of Arizona–Tucson, College of Pharmacy, Skaggs Center of Pharmaceutical Sciences, Tucson, AZ, USA Abstract: The aim of this study was to design and develop respirable antibiotics moxifloxacin (MOXI) hydrochloride and ofloxacin (OFLX) microparticles and nanoparticles, and multifunctional antibiotics particles with or without lung surfactant 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) for targeted dry powder inhalation delivery as a pulmonary nanomedicine. Particles were rationally designed and produced by advanced spray-drying particle engineering from an organic solution in closed mode (no water) from dilute solution. Scanning electron microscopy indicated that these particles had both optimal particle morphology and surface morphology, and the particle size distributions were suitable for pulmonary delivery. Comprehensive and systematic physicochemical characterization and in vitro aerosol dispersion performance revealed significant differences between these two fluoroquinolone antibiotics following spray drying as drug aerosols and as cospray-dried antibiotic drug: DPPC aerosols. Fourier transform infrared spectroscopy and confocal Raman microspectroscopy were employed to probe composition and interactions in the solid state. Spray-dried MOXI was rendered noncrystalline (amorphous) following organic solution advanced spray drying. This was in contrast to spray-dried OFLX, which retained partial crystallinity, as did OFLX:DPPC powders at certain compositions. Aerosol dispersion performance was conducted using inertial impaction with a dry powder inhaler device approved for human use. The present study demonstrates that the use of DPPC offers improved aerosol delivery of MOXI as cospray-dried microparticulate/nanoparticulate powders, whereas residual partial crystallinity influenced aerosol dispersion of OFLX and most of the compositions of OFLX:DPPC inhalation powders. Keywords: lung infection, respiratory, lung surfactant, solid-state particle engineering design, aerosol, fluoroquinolone antibiotic drug delivery
format	article
author	Duan J Vogt FG Li X Hayes D Jr Mansour HM
author_facet	Duan J Vogt FG Li X Hayes D Jr Mansour HM
author_sort	Duan J
title	Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery
title_short	Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery
title_full	Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery
title_fullStr	Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery
title_full_unstemmed	Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery
title_sort	design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (dppc) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/69cb2ec632664caaa185b111daa0b725
work_keys_str_mv	AT duanj designcharacterizationandaerosolizationoforganicsolutionadvancedspraydriedmoxifloxacinandofloxacindipalmitoylphosphatidylcholinedppcmicroparticulatenanoparticulatepowdersforpulmonaryinhalationaerosoldelivery AT vogtfg designcharacterizationandaerosolizationoforganicsolutionadvancedspraydriedmoxifloxacinandofloxacindipalmitoylphosphatidylcholinedppcmicroparticulatenanoparticulatepowdersforpulmonaryinhalationaerosoldelivery AT lix designcharacterizationandaerosolizationoforganicsolutionadvancedspraydriedmoxifloxacinandofloxacindipalmitoylphosphatidylcholinedppcmicroparticulatenanoparticulatepowdersforpulmonaryinhalationaerosoldelivery AT hayesdjr designcharacterizationandaerosolizationoforganicsolutionadvancedspraydriedmoxifloxacinandofloxacindipalmitoylphosphatidylcholinedppcmicroparticulatenanoparticulatepowdersforpulmonaryinhalationaerosoldelivery AT mansourhm designcharacterizationandaerosolizationoforganicsolutionadvancedspraydriedmoxifloxacinandofloxacindipalmitoylphosphatidylcholinedppcmicroparticulatenanoparticulatepowdersforpulmonaryinhalationaerosoldelivery
_version_	1718403443829243904

Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery

Ejemplares similares